Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas
Correlation of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging and Tumor Histopathology in Patients With Infiltrating Gliomas
Who can join
Ages 18 to 80 · All sexes
Full eligibility criteria
Inclusion Criteria: * • Patients with a new brain lesion interpreted as suspected infiltrating gliomas including but not limited to (diffuse astrocytoma WHO grade 2; oligodendroglioma WHO grade 2 and 3; anaplastic astrocytoma WHO grade 3; astrocytoma WHO grade 4), OR, patients with prior history of infiltrating glioma scheduled for surgery for tumor biopsy or resection. * Ages 18-80, including male and female * Suitable to undergo contrast-enhanced MRI * Negative serum pregnancy test Exclusion Criteria: * Inability to undergo MRI scan * Inability to receive IV contrast secondary to severe reaction or renal insufficiency.
About the study
The purpose of this study is to examine the safety and feasibility of performing hyperpolarized metabolic MRI in the diagnosis of brain tumor. This study will also assess the accuracy of hyperpolarized metabolic MRI to diagnose intermediate to patients with infiltrating gliomas and examine the added utility of metabolic MRI over standard MRI imaging
The FDA is allowing the use of hyperpolarized \[1-13C\] pyruvate (HP 13C-pyruvate) in this study.
Up to 5 patients may take part in this study at the University of Maryland, Baltimore (UMB).
What is being tested
- Hyperpolarized 13C-Pyruvate (drug)
Sponsor: University of Maryland, Baltimore · Participants: 5 · Started: Aug 11, 2020
Contact the study team
- Rosy Njonkou Tchoquessi · Phone: 4107066445
Official record on ClinicalTrials.gov — NCT04772456
Locations in the U.S.
| Maryland | Rosy Njonkou Tchoquessi, Baltimore |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.